country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-187718

Copy Link Print Information

CGC-11150

CGC-11150 is a decamine-based polyamine analog that acts as a voltage-dependent pore blocker of Kir channels. CGC-11150 produces voltage-dependent pore block similar to that of Spermine (HY-B1777) in recombinant Kir6.2^{[N160D, L164C, C166S, Δ36]} + SUR1 channels, but with faster on and off rates. CGC-11150 inhibits the development of and induces regression of laser-induced choroidal neovascularization (CNV). CGC-11150 is used in studies related to choroidal neovascularization.

For research use only. We do not sell to patients.

CAS No.: 304911-08-8
Formula: C₄₀H₉₀N₁₀·10HCl
Molecular Weight:1075.82

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

CGC-11150 Chemical Structure

CAS No.: 304911-08-8

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

CGC-11150 (1 μM) induces voltage-dependent inward rectification of Kir6.2-rec channels expressed in COSm6 cells, with blocking characteristics similar to spermine but slightly reduced potency and faster on/off rates^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Local Vascular Regulation

CGC-11150 (10-20 mg/kg; i.p.; 2 to 3 times per week; for 14 days) causes a slight reduction in CNV area, but exhibits poor tolerability at high doses^[2].
CGC-11150 (20 μg; intravitreal injection; administered on day 0 and day 7 post-injury) reduces the CNV area by approximately 40% in a mouse model of laser-induced choroidal neovascularization^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J (female, 4 to 5 weeks old, laser-induced rupture of Bruch’s membrane)^[2]
Dosage:

10 mg/kg; 20 mg/kg (i.p.); 20 μg (intravitreous)
Administration:

i.p.; twice a week; 14 days; i.p.; three times a week; 14 days; intravitreous; on days 0 and 7 after injury
Result:

Caused a small reduction in CNV lesion area.
Was not well tolerated (several mice died), but surviving mice showed a small reduction in CNV lesion area comparable to the 10 mg/kg dose.
Resulted in an approximately 40% reduction in CNV lesion area compared to vehicle-treated or untreated eyes.
Caused retinal damage.

Chemical Information

CAS No. 304911-08-8
Molecular Weight 1075.82
Formula C₄₀H₉₀N₁₀·10HCl
SMILES

CCNCCCCNCCCCNCCCCNCCCCNC/C=C\CNCCCCNCCCCNCCCCNCCCCNCC.Cl.[10]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Loussouarn G, et al. Molecular basis of inward rectification: structural features of the blocker defined by extended polyamine analogs. Molecular pharmacology. 2005 Aug;68(2):298-304.

[2]. Lima e Silva R, et al. Suppression and regression of choroidal neovascularization by polyamine analogues. Investigative ophthalmology & visual science. 2005 Sep;46(9):3323-30.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote